What this Trial Is About

Researchers are evaluating the feasibility, acceptability, and early effectiveness of EndeavorRx, an FDA-approved digital attentional-control training program, in children and teenagers aged 8 to 16 who survived acute lymphoblastic leukemia (ALL) or brain tumors and are at least one year past their treatment. These survivors often face lasting cognitive challenges affecting attention, working memory, and executive functions, which impact daily life, social interactions, school performance, and overall quality of life. This pilot randomized controlled trial aims to study whether EndeavorRx can help improve attention difficulties in this group. Participants will be randomly assigned to either use EndeavorRx, which involves playing an action video game with adaptive difficulty through tasks requiring attention and sensorimotor skills, or to an active control group playing a digital word game designed to match engagement and time spent but targeting different cognitive areas. Both interventions involve sessions lasting 25-30 minutes per day, five days a week, for one month. The study plans to enroll about 50 survivors across three pediatric oncology centers, with 40 participants meeting attention difficulty criteria proceeding to randomization. During the study, children will undergo cognitive testing before and after the intervention period, while parents will complete questionnaires about their child's functioning. Researchers will monitor patient and family interest, adherence to the training schedule, ease of use, and satisfaction with the program. These measures will help assess the feasibility of this training, along with preliminary data on improvements in attention based on performance tests and parent reports. The total involvement includes screening, one month of training, and follow-up assessments.

Feasibility/Acceptability of Attentional-Control Training in Survivors